Most selected CNVs in posttreatment metastatic tumours were also found to be selected in pretreatment metastatic samples, except EP300 amplification, FBXW7 deletion and PTEN deletion (Fig. 2c and e). This evidence concerns the gene EP300 and metastatic neoplasm.